Neurogene's stock price collapsed by 34.8% in pre-market trading after announcing data from the Phase I/II Rett syndrome ...
Cerevance has announced positive outcomes from its Phase I trial of CVN293, a drug candidate designed to treat ...
Arch Biopartners has dosed the first patient in Canada in its Phase II clinical trial of LSALT peptide (Metablok) for acute ...
ViiV Healthcare has reported results from a trial of Dovato, a two-drug regimen consisting of dolutegravir/lamivudine ...
AbbVie’s stock price fell over 12% after emraclidine failed to meet its primary endpoints in the company’s Phase II ...